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Abstract
In the HERS trial, hormone therapy did not reduce the risk of coronary events. In
post hoc analyses, treatment was associated with early härm and late benefit.
Accordmg to one hypothesis, a risk factor may well distmguish a susceptible
subgroup with early events associated with hormone therapy from a nonsusceptible
subgroup who benefit from hormone therapy. In Simulation studies, it appeared that
only a susceptibility factor with a low prevalence (3-5%) and a high risk ratio (13-
25-fold) can produce the pattern of nsks seen in HERS. The number of candidate
factors is hkely to be small.
Smce observational studies have consistently suggested that
the use of hormone replacement therapy in postmenopausal
women reduces the risk of coronary heart disease,1'2 the
results of the Heart and Estrogen/progestin Replacement
Study (HERS) were unexpected.3 In this randomized clmical
trial of secondary prevention, combmed hormone therapy was
no better than placebo at preventing coronary events in post-
menopausal women (risk ratio [RR] = 0.99, 95% confidence
mterval [CI] = 0.81-1.22). In post hoc analyses, treatment
was associated with a pattern of early härm and late benefit —
a risk ratio of 1.52 (95% CI = 1.01-2.29) durmg the first year
of follow-up and a risk ratio of 0.75 (95% CI = 0.50-1.13)
durmg follow-up years 4 and 5.
While chance fluctuations around a null finding of 0.99
remain one important potential explanation,4 the HERS
mvestigators offered another broad hypothesis to explam this
pattern of risks — the possibihty of 'an immediate prothrom-
botic, proarrhythmic or proischemic effect of treatment that
is gradually outweighed by a beneficial effect on the under-
lymg progression of atherosclerosis'.3 We recently reported
an mteraction between hormone replacement therapy and the
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prothrombm vanant on the risk of myocardial mfarction m
hypertensive women.5 If the hypothesis of an mteraction with
a risk factor that disposes to early härm is true, there may be
a susceptible subgroup who have early events associated with
hormone replacement therapy and another nonsusceptible
subgroup who benefit from hormone replacement therapy.
Identification of such a susceptibility factor would enable
chmcians to target hormone therapy to those postmenopausal
women who are most hkely to benefit and avoid usmg it m
those who might expenence adverse events. An understanding
of the hkely charactenstics of this hypothetical susceptibility
factor, such äs its prevalence and its effect size, might help
in the search.
We undertook a series of Simulation studies to estimate the
prevalence of the susceptible subgroup and, if exposed to hor-
mone replacement therapy, their risk ratio for coronary events
— a combination of prevalence and risk that could reproduce
the results of the HERS trial. In all simulations, we assumed
that there were 1400 women m each arm of the trial and that
the event rate was 30 coronary events per 1000 person-years
m the control group. For the effect of oestrogens on risk ratio
for coronary events in the nonsusceptible subgroup, we tned
several assumptions: (i) risk ratios of 0.9 in year l, 0.8 m year 2,
and 0.7 in years 3-5; (11) risk ratios of 0.75 m all years; and
(m) risk ratios of 0.70 in all years. This first set of assumptions
was based loosely on the lipid-lowermg tnals, where the
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Table l Prevalence and nsk ratio among susceptibles foi hormone-replacemcnt therapy in two simulations
Simulation l Simulation 2

























































































































RR = nsk ratio for coronaiy events among the susceptibles exposed to hoimone leplacement therapy In Simulation l, the nsk ratlos for coronary
events among nonsusceptibles usmg Hormone replacement therapy were assumed to be 0 9 in year l, 0 8 m year 2, and 0 7 in years 3-5 In Simulation
2, the risk ratios foi coronary events among the nonsusceptibles usmg hormone leplacement therapy were assumed to be 0 75 m each year
Pascal source code and Output for the simulations included in the table are available on request
survival curves separate only gradually over the first 1-2
years of the tnal.6
In the simulations, we vaned the prevalence of the susceptib-
ility factor from 1% to 25% and the nsk ratio for the effect
of hormone replacement therapy on the nsk of coronary dis-
ease from l to 25 in the susceptible group. In other words,
each Simulation included 625 combinations of a prevalence
and a risk ratio. For each combmation and for each year of
follow-up, we calculated the numbers of events and subjects
at nsk in the treated group and the placebo group, and these
numbers were used to estimate the overall risk ratio associated
with hormone therapy durmg each year of follow-up. The
event rate m the simulated placebo group was constant. In
the simulated hormone replacement therapy group, the total
number of events durmg any one year was the sum of the
events m the large group (99-75%) of nonsusceptibles whose
relative nsk ranged from 0.9 to 0.7 m the vanous simulations
and the events in the small group (1-25%) of susceptibles
whose relative risk ranged from 2.0 to 25.0.
Table l summanzes the results of two simulations. The top
hne of Table l mcludes the fmdmgs from HERS, which we
wished to duphcate m the Simulation For each prevalence,
one of the 25 simulated risk ratios was selected m an effort to
reproduce the year l nsk of 1.52 and the year 4-5 risk of 0.75.
The question is really this: for which combmation of preval-
ences and risks can the overall fmdmgs for the population be
at once 1.52 in year l and 0 75 in years 4-5? In Table l, the
answer is not many. A susceptibility factor with a prevalences
of 1-2%, even when nsk ratios were 25, could not attain a
year l level of risk of 1.52. A susceptibility factor with a prev-
alence of 3-5%, when the risk ratios were 13-25, provided
perhaps the best fit. For a factor with a prevalence of 6-10%,
when the estimated year l nsks were close to 1.52, the year 4-
5 risks were at or above 0.88. For prevalences above 10%, the
year 4-5-values did not go below 1.0. Assuming the effect of
hormone replacement therapy m the nonsusceptible group
was 0 70 across all years shifted the best fit only shghtly to
prevalences of 4-6% with risk ratios of 20 to 16 (data not
shown).
In this Simulation, we assumed that a smgle fixed factor
such äs a genetic trait confers an mcreased coronary risk to
a small subgroup who are exposed to hormone replacement
therapy while the rest of the population expenences various
levels of a niodest benefit from hormone replacement therapy.
Under this model, it appears that only a factor with a low
prevalence and a high nsk ratio can reproduce the pattern of
risks seen m HERS. The number of candidate factors that meet
these cnteria is likely to be small.
This conclusion about the charactenstics of the unknown
susceptibility factor depends upon several assumptions. We
assumed that there was only one susceptibility factor and that
its nsk ratio was constant over time. Moreover, we did not
take mto account a possible vanabihty around these pomt
estimates. Had we done so, the ränge of potential preval-
ences and risk ratios would have been larger. Indeed, samplmg
vanabihty around the null of 0.99 is another reasonable
explanation for the HERS fmdmgs. The model with a fixed
factor would not be appropriate if multiple factors are mvolved,
if the factor is one such äs smokmg, that may change with
time, or if physiological adjustments modify the mteraction
over time.
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